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Fatemeh Sheikhmoonesi* and Seyyedeh Fatemeh Bahari SaraviAbstract
Background: Deep venous Thrombosis is a serious, possible life threatening event which is often ignored in
psychiatric Settings.
Purpose: In this paper three cases of deep venous Thrombosis (DVT) following the use of olanzapine and
risperidone are presented.
Methods: The data of Three patients was collected from hospital records.
Results: The patients were in good general physical health and had no personal or familial history of DVT. The
patients were not overweight (BMI < 25) but they suffered from DVT after initiating risperidone and olanzapine.
Conclusion: Risk of DVT exists in patients under treatment with atypical antipsychotics in spite of no pre existing
risk factor.
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Deep venous thrombosis (DVT) and pulmonary embo-
lism (PE) are frequent illnesses with an annual incidence
of 1 per 1000 persons and a mortality rate above 15% in
the first 3 months after diagnosis [1]. Risk of DVT is
relatively more in psychiatric patients rather than people
who are mentally healthy [2], especially in Paients suffer-
ing from schizophrenia and bipolar disorder [3]. In a
case reported by Zornberg & Jick, a significantly increa-
sed risk of DVT was seen in patients receiving first ge-
neration antipsychotics, particularly in the first months
of the treatment [4]. It is believed that Antipsychotics
may induce pathological blood clotting via sedating them
as well as reducing motor activity, metabolic Syndrome
such as obesity and hyperprolactinemia [5].
The patients’ sedation, immobilization or psychopatho-
logical symptoms, often interfere with the diagnosis of
DVT, therefore, it may not always be recognized at first
[6].
In this report three psychiatric patients who deve-
loped DVT after using olanzapine and risperidon are* Correspondence: fmoonesi@mazums.ac.ir
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found in these cases. Nevertheless, their condition sug-
gests a possible association between atypical antipsycho-
tics and DVT in the absence of any pre- existing risk
factors. Written informed consents were obtained from
the patients for publication of this report.
Case 1
The patient was a 38- year- old female with a diagnosis
of depressive episode in course of bipolar 1 disorder,
according to DSM-IV-TR presenting with depressed
mood, food refusal and isolation.she had discontinued
her drugs since 4 weeks before.
Routine physical examination and laboratory tests
were normal. There was not familial history of psychi-
atric disorder. The patient was not overweight (body
mass index: 22). She also had no identified cardiovascu-
lar risk factor. Due to the intensity of symptoms she
underwent ECT (electroconvulsive therapy) and received
Risperidone 4 mg/daily and Biperiden 2 mg/daily. Two
weeks later swelling was seen in her right leg. A diagno-
sis of DVT was suspected and she was initiated on high
dose low-molecular-weight heparin. After 24 hours of
initiation of the treatment, patient died due to cardiac
arrest.see BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly cited.
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A 24- year- old female was admitted to hospital due to a
psychotic disorder (NOS) according to DSM-IV-TR. She
had visual and auditory hallucination and persecutory
delusion. Three years prior to this admission, the patient
was diagnosed with paranoid schizophrenia. However
she did not have a good compliance. Therefore she had
been admitted Several times in psychiatric ward. When
she referred to our hospital, she have not received any
drug for two months. She was treated with electrocon-
vulsive therapy (ECT), Risperidone 6 mg/day and Biperi-
den 4 mg/daily. After two months she complained of
severe pain in her right leg. Clinical examination
revealed right lower limb swelling. Doppler ultrasonog-
raphy and Contrast venography in the right lower limb
confirmed the diagnosis of DVT, she underwent thromb-
ectomy and consequently swelling was resolved.
Case 3
A 64 – year – old male was referred to psychiatric
ward due to aggression, grandiose delusion, hyposomnia
(decreased need for sleep) and flight of idea . His medi-
cal history showed that he was diagnosed with bipolar 1
disorder according to DSM-IV-TR,around ten years prior
to this study.on this last admission, he initiated on sodium
valproate 1200 mg/day, olanzapine 15 mg/day, biperiden
4 mg/day. After three weeks, he suffered from swelling in
left leg. All of the mentioned drugs were discontinued
which led to his full recovery.
Discussion
The link between conventional antipsychotic medica-
tions and venous Thromboembolism (VTE) was first
suggested in the 1950s. However, there are few case
reports maintaining an association between atypical an-
tipsychotics and VTE and they are mainly related to
Clozapine [7]. Atypical antipsychotics have been associa-
ted with sedation, a more sedentary lifestyle and weight
gain, all of which are predisposing factors for VTE [8].
However, these are unlikely to be etiologic factors in
early thromboembolic occurrence.
A previous case study described three elderly patients
(an 89- year – old male, a 78 – year – old male and an
83- year – old female) in whom olanzapine therapy was
associated with VTE [9]. But the cases presented in this
paper are different since all three were under 65 years
old. Therefore, it could be suggested that Olanzapine
could result in thrombosis at any age.
In another case report massive pulmonary embolism
was found in a 27- year – old obese Somali man, tem-
porally related to ingestion of olanzapine over dose
(nearly 150 mg) [10].
Thromboembolic complications have not previously
been reported in patients taking low doses of olanzapine.So far, the biological mechanisms responsible for this
possible adverse drug reaction have not been found, but
a number of hypotheses have been made . For instance,
antipsychotics like olanzapine and risperidone that are
antagonist of 5 HT2 receptors, so, they can induce in-
crease of serotonin which in turn might provoke en-
hanced aggregation of platelets, thereby increasing the
risk for thrombosis [11].
Patients being treated with olanzapine and risperidone
should be monitored clinically for venous thrombo-
embolism to ensure early detection and intervention,
and a possible discontinuation of treatment with olanza-
pine and risperidone should be considered if the diagno-
sis of venous thromboembolism is made.
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